Results 181 to 190 of about 51,890 (248)
Peptide‐based responsive molecular fluorescent probes for precision oncology
Responsive Materials, EarlyView.Peptide‐based responsive fluorescent probes have emerged as adaptive functional materials for precision tumor theranostics, combining tumor‐selective recognition, programmable stimulus responsiveness, and modular tunability. They enable high‐contrast imaging, intraoperative guidance, real‐time monitoring, and multimodal applications, while next ...
Xing Wang +6 more
wiley +1 more source
Unusual Cutaneous and Lymphatic Findings in an Adult Patient
JEADV Clinical Practice, EarlyView.
Sarah Preis +4 more
wiley +1 more source
VIEW, EarlyView.Nanobodies, derived from the variable domains of camelid heavy‐chain‐only antibodies, have emerged as transformative biomedical tools due to their nanoscale size, exceptional stability, and unique capacity to recognize cryptic epitopes. This review provides a comprehensive overview of the field, outlining the structural and biochemical features of ...
Zhenrui Ye, Xianyang Li, Meixiao Zhan
wiley +1 more source
Risk of Cancer With Hormone Replacement Therapy: A Narrative Review
BJOG: An International Journal of Obstetrics &Gynaecology, EarlyView.ABSTRACT Hormone replacement therapy (HRT) remains the cornerstone of menopausal symptom management, effectively alleviating vasomotor symptoms and genitourinary syndrome, whilst mitigating long‐term risks such as osteoporosis. However, despite an increasing body of evidence on the relative safety of HRT, earlier studies that demonstrated an increased ...
Gabriella Yongue +3 more
wiley +1 more source
A phase II trial of pan-KIR2D blockade with IPH2101 in smoldering multiple myeloma
Haematologica, 2014 Neha Korde +22 more
doaj +1 more source
Asia-Pacific Journal of Clinical Oncology, EarlyView.RVD with weekly bortezomib dosing in real‐world newly diagnosed transplant‐ineligible myeloma shows comparable efficacy and reduced toxicity compared to twice‐weekly trial protocols. ABSTRACT Background Lenalidomide, bortezomib, and dexamethasone (RVD) remains a standard of care regimen for newly diagnosed multiple myeloma in centers without access to ...
Samantha Kurniawan +17 more
wiley +1 more source
T Cells Dysfunction in Multiple Myeloma
Linyu Cai,1 Liping Zuo,1 Guangqi Wang,1 Qun Li,1 Chi Ma,1 Jianghua Wu,1 Chunyan Sun,1 Yu Hu1,2 1Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, 430022, People’s Republic of ...
Wu J +7 more
core
Novel Bispecific Engagers Targeting the CεmX Domain of mIgE‐Expressing Cells
Allergy, EarlyView.We developed bispecific TCE & NKCE targeting the CεmX domain of mIgE to eliminate IgE‐producing cells. Both constructs demonstrated potent, specific, dose‐dependent cytotoxicity and selective immune activation in vitro. These results highlight their promise as off‐the‐shelf, potentially curative therapeutics for IgE‐associated allergic diseases ...
Constantin Möller +16 more
wiley +1 more source
Alimentary Pharmacology &Therapeutics, EarlyView.HBV reactivation incidence varied across immunosuppressive and chemotherapeutic agents. Clinically meaningful HBV reactivation was also observed in patients receiving corticosteroids and conventional immunosuppressive therapies. ABSTRACT Background Data on the incidence of hepatitis B virus reactivation (HBVr) remain limited. In Japan, patients who are
Kazuhiko Ikeuchi +8 more
wiley +1 more source